178 related articles for article (PubMed ID: 9391119)
1. A point mutation in the MET oncogene abrogates metastasis without affecting transformation.
Giordano S; Bardelli A; Zhen Z; Menard S; Ponzetto C; Comoglio PM
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13868-72. PubMed ID: 9391119
[TBL] [Abstract][Full Text] [Related]
2. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis.
Bardelli A; Basile ML; Audero E; Giordano S; Wennström S; Ménard S; Comoglio PM; Ponzetto C
Oncogene; 1999 Feb; 18(5):1139-46. PubMed ID: 10022119
[TBL] [Abstract][Full Text] [Related]
3. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
Jeffers M; Koochekpour S; Fiscella M; Sathyanarayana BK; Vande Woude GF
Oncogene; 1998 Nov; 17(21):2691-700. PubMed ID: 9840933
[TBL] [Abstract][Full Text] [Related]
4. Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential.
Bardelli A; Longati P; Gramaglia D; Stella MC; Comoglio PM
Oncogene; 1997 Dec; 15(25):3103-11. PubMed ID: 9444958
[TBL] [Abstract][Full Text] [Related]
5. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.
Bardelli A; Longati P; Gramaglia D; Basilico C; Tamagnone L; Giordano S; Ballinari D; Michieli P; Comoglio PM
Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14379-83. PubMed ID: 9826708
[TBL] [Abstract][Full Text] [Related]
6. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.
Ponzetto C; Bardelli A; Zhen Z; Maina F; dalla Zonca P; Giordano S; Graziani A; Panayotou G; Comoglio PM
Cell; 1994 Apr; 77(2):261-71. PubMed ID: 7513258
[TBL] [Abstract][Full Text] [Related]
7. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
8. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
9. MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
Williams TA; Longati P; Pugliese L; Gual P; Bardelli A; Michieli P
J Cell Physiol; 1999 Dec; 181(3):507-14. PubMed ID: 10528237
[TBL] [Abstract][Full Text] [Related]
10. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells.
Jeffers M; Rong S; Anver M; Vande Woude GF
Oncogene; 1996 Aug; 13(4):853-6. PubMed ID: 8761307
[TBL] [Abstract][Full Text] [Related]
11. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Michieli P; Basilico C; Pennacchietti S; Maffè A; Tamagnone L; Giordano S; Bardelli A; Comoglio PM
Oncogene; 1999 Sep; 18(37):5221-31. PubMed ID: 10498872
[TBL] [Abstract][Full Text] [Related]
12. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis.
Saucier C; Papavasiliou V; Palazzo A; Naujokas MA; Kremer R; Park M
Oncogene; 2002 Mar; 21(12):1800-11. PubMed ID: 11896612
[TBL] [Abstract][Full Text] [Related]
13. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.
Rong S; Bodescot M; Blair D; Dunn J; Nakamura T; Mizuno K; Park M; Chan A; Aaronson S; Vande Woude GF
Mol Cell Biol; 1992 Nov; 12(11):5152-8. PubMed ID: 1406687
[TBL] [Abstract][Full Text] [Related]
14. Activating mutations for the met tyrosine kinase receptor in human cancer.
Jeffers M; Schmidt L; Nakaigawa N; Webb CP; Weirich G; Kishida T; Zbar B; Vande Woude GF
Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11445-50. PubMed ID: 9326629
[TBL] [Abstract][Full Text] [Related]
15. Ron kinase transphosphorylation sustains MET oncogene addiction.
Benvenuti S; Lazzari L; Arnesano A; Li Chiavi G; Gentile A; Comoglio PM
Cancer Res; 2011 Mar; 71(5):1945-55. PubMed ID: 21212418
[TBL] [Abstract][Full Text] [Related]
16. Activation of the JNK pathway is essential for transformation by the Met oncogene.
Rodrigues GA; Park M; Schlessinger J
EMBO J; 1997 May; 16(10):2634-45. PubMed ID: 9184210
[TBL] [Abstract][Full Text] [Related]
17. FOXC2 promotes colorectal cancer metastasis by directly targeting MET.
Cui YM; Jiao HL; Ye YP; Chen CM; Wang JX; Tang N; Li TT; Lin J; Qi L; Wu P; Wang SY; He MR; Liang L; Bian XW; Liao WT; Ding YQ
Oncogene; 2015 Aug; 34(33):4379-90. PubMed ID: 25381815
[TBL] [Abstract][Full Text] [Related]
18. Scatter factor receptors are key players in a unique multistep program leading to invasive growth.
Bardelli A; Comoglio PM
Ciba Found Symp; 1997; 212():133-44; discussion 144-7. PubMed ID: 9524768
[TBL] [Abstract][Full Text] [Related]
19. Different point mutations in the met oncogene elicit distinct biological properties.
Giordano S; Maffe A; Williams TA; Artigiani S; Gual P; Bardelli A; Basilico C; Michieli P; Comoglio PM
FASEB J; 2000 Feb; 14(2):399-406. PubMed ID: 10657996
[TBL] [Abstract][Full Text] [Related]
20. The role of non-ras transforming genes in chemical carcinogenesis.
Cooper CS
Environ Health Perspect; 1991 Jun; 93():33-40. PubMed ID: 1685444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
